Remove 2022 Remove Immune Response Remove Virus
article thumbnail

Phages could help to tackle antimicrobial resistance

Drug Target Review

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immune response.

RNA 59
article thumbnail

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineAdvance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

The Pharma Data

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. About Novavax. Novavax, Inc.?(Nasdaq: Source link.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CureVac provides update on Phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV

The Pharma Data

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52
article thumbnail

Blocking enzyme could hold the key to preventing, treating severe COVID-19

The Pharma Data

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.

article thumbnail

PFIZER AND BIONTECH ANNOUNCE COLLABORATION WITH BIOVAC TO MANUFACTURE AND DISTRIBUTE COVID-19 VACCINE DOSES WITHIN AFRICA

The Pharma Data

Biovac will obtain drug substance from facilities in Europe, and manufacturing of finished doses will commence in 2022. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine.

Vaccine 52
article thumbnail

A Visual Guide to Genome Editors

Codon

The core of the CRISPR immune response is a guide RNA (gRNA) that binds to a CRISPR-associated (Cas) protein. If the same virus invades the cell a second time, the gRNA’s spacer sequence will bind to the matching viral DNA sequence, then be cut by the Cas protein.

DNA 78
article thumbnail

T-cell receptors offer window to the cell for a new class of cancer therapeutics

Drug Target Review

Each T cell expresses a TCR specific for an HLA‑presented peptide signal, and when that signal is detected a T cell expressing the relevant TCR can launch a complex array of immune effector responses that can suppress or destroy tumours or virus-infected cells. Journal for ImmunoTherapy of Cancer 10:e004281 (2022).